Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X:
“ADCs combine the potency of chemo with the PK of mAbs. This translates into increased antitumor activity, but also in delayed toxicities. The most common, with T-DXd: nausea. Check this interesting Annals Oncology editorial on the ERICA randomized trial.”
Author: K. Jordan
More posts featuring Paolo Tarantino.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.